Hapvida and Plamed are under scrutiny by the Brazilian competition authority for failing to comply with structural remedies imposed on them when their deal was approved in February.The parties asked the Administrative Council for Economic Defense, or CADE, to extend the original deadline for the sale of assets involving Plamed's client portfolios